A detailed history of Nuveen Asset Management, LLC transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 156,573 shares of EYPT stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
156,573
Previous 123,542 26.74%
Holding current value
$1.36 Million
Previous $2.86 Million 13.35%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$19.93 - $29.71 $658,307 - $981,351
33,031 Added 26.74%
156,573 $3.24 Million
Q4 2023

Feb 14, 2024

SELL
$5.71 - $24.13 $298,747 - $1.26 Million
-52,320 Reduced 29.75%
123,542 $2.86 Million
Q3 2023

Nov 14, 2023

BUY
$7.99 - $15.36 $79,876 - $153,553
9,997 Added 6.03%
175,862 $1.41 Million
Q2 2023

Aug 14, 2023

BUY
$3.03 - $9.0 $188,063 - $558,603
62,067 Added 59.8%
165,865 $1.44 Million
Q1 2023

May 15, 2023

SELL
$2.28 - $5.04 $9,961 - $22,019
-4,369 Reduced 4.04%
103,798 $305,000
Q4 2022

Feb 14, 2023

SELL
$2.37 - $7.2 $17,144 - $52,084
-7,234 Reduced 6.27%
108,167 $379,000
Q3 2022

Nov 14, 2022

SELL
$6.96 - $11.12 $5,755 - $9,196
-827 Reduced 0.71%
115,401 $913,000
Q2 2022

Aug 15, 2022

SELL
$7.25 - $12.71 $55,332 - $97,002
-7,632 Reduced 6.16%
116,228 $915,000
Q1 2022

May 16, 2022

BUY
$8.67 - $14.11 $600,085 - $976,609
69,214 Added 126.66%
123,860 $1.58 Million
Q4 2021

Feb 14, 2022

SELL
$10.18 - $18.4 $70,364 - $127,180
-6,912 Reduced 11.23%
54,646 $787,000
Q3 2021

Nov 12, 2021

SELL
$7.51 - $11.72 $5,512 - $8,602
-734 Reduced 1.18%
61,558 $680,000
Q2 2021

Aug 16, 2021

BUY
$8.69 - $11.08 $541,317 - $690,195
62,292 New
62,292 $560,000

Others Institutions Holding EYPT

About EyePoint Pharmaceuticals, Inc.


  • Ticker EYPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,072,200
  • Market Cap $296M
  • Description
  • EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...
More about EYPT
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.